The UCSF Alzheimer's Disease Research Center (ADRC) has made remarkable progress in our first 9 years, developing diagnostic approaches to dementia that are elucidating the phenotypic, genetic and molecular heterogeneity of Alzheimer's disease (AD), frontotemporal dementia (FTD), and Creutzfeldt-Jakob disease (CJD). The unique clinical cohorts, biospecimens, and images that we collect in the ADRC have facilitated these successes. Talented scientists mentored through our ADRC are making major contributions to the understanding of dementia. ADRC research has steadily increased. We are defining distinctive clinical subtypes of AD, FTD, and CJD that predict specific molecular and physiological mechanisms for dementia, while improving early recognition and tracking of transitions from normal aging to mild cognitive impairment (MCI) and dementia. These efforts will continue in parallel with drug development and pursuit of clinical trials with researchers who work with the ADRC. We will explore the heterogeneous features of AD, FTD-spectrum disorders, and CJD in the early stages with the goal of predicting their physiological, genetic, and molecular underpinnings. We will leverage cohorts in the ADRC and the powerful neuroscience community at UCSF and beyond to stimulate new diagnostic and treatment efforts for AD, FTD and CJD. We will increase understanding of the unique cultural and biological features of aging Chinese-Americans. We will develop innovative approaches to data management and biostatistics that we will share. The Education Core will be responsible for training new dementia leaders, while educating the medical and lay communities about non-AD dementias and non-amnestic subtypes of AD. We will perform three new projects: Project 1: Dr. Gil Rabinovici will compare and contrast early onset AD, late onset AD, and apoE4+ versus apoE4- patients to improve diagnostic accuracy in AD. Project 2: Dr. Marilu Gorno-Tempini will study developmental and immunological factors that influence the phenotype in PPA. Project 3: Dr. Yadong Huang will reprogram human skin fibroblasts into induced pluripotent stem cells and convert them into neurons from E4/E4 or E3/3 patients and healthy controls. Pathological substrates and gene expression will be compared.

Public Health Relevance

The UCSF ADRC will focus on Alzheimer's (AD) and related dementias. We bring unique skills to early diagnosis, improved clinical and imaging tests and new treatment approaches. We bring exceptional educational programs to professionals, patients and families.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
2P50AG023501-11
Application #
8677141
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (J1))
Program Officer
Phelps, Creighton H
Project Start
2004-04-01
Project End
2019-03-31
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
11
Fiscal Year
2014
Total Cost
$2,019,359
Indirect Cost
$634,974
Name
University of California San Francisco
Department
Neurology
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Barton, Cynthia; Ketelle, Robin; Merrilees, Jennifer et al. (2016) Non-pharmacological Management of Behavioral Symptoms in Frontotemporal and Other Dementias. Curr Neurol Neurosci Rep 16:14
Rabinovici, Gil D (2016) Amyloid biomarkers: pushing the limits of early detection. Brain 139:1008-10
Mez, Jesse; Mukherjee, Shubhabrata; Thornton, Timothy et al. (2016) The executive prominent/memory prominent spectrum in Alzheimer's disease is highly heritable. Neurobiol Aging 41:115-21
Schott, Jonathan M; Crutch, Sebastian J; Carrasquillo, Minerva M et al. (2016) Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimers Dement 12:862-71
Yokoyama, Jennifer S; Desikan, Rahul S (2016) Association of Alzheimer Disease Susceptibility Variants and Gene Expression in the Human Brain-Reply. JAMA Neurol 73:1255
Voyle, N; Kim, M; Proitsi, P et al. (2016) Blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins. Transl Psychiatry 6:e719
Mair, Waltraud; Muntel, Jan; Tepper, Katharina et al. (2016) FLEXITau: Quantifying Post-translational Modifications of Tau Protein in Vitro and in Human Disease. Anal Chem 88:3704-14
Oh, Hwamee; Madison, Cindee; Baker, Suzanne et al. (2016) Dynamic relationships between age, amyloid-β deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease. Brain 139:2275-89
LoBue, Christian; Denney, David; Hynan, Linda S et al. (2016) Self-Reported Traumatic Brain Injury and Mild Cognitive Impairment: Increased Risk and Earlier Age of Diagnosis. J Alzheimers Dis 51:727-36
Nascimento, Camila; Suemoto, Claudia K; Rodriguez, Roberta D et al. (2016) Higher Prevalence of TDP-43 Proteinopathy in Cognitively Normal Asians: A Clinicopathological Study on a Multiethnic Sample. Brain Pathol 26:177-85

Showing the most recent 10 out of 390 publications